{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:42:05Z","timestamp":1788381725296,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.beem.2014.08.010","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:10:07Z","timestamp":1409098207000},"page":"219-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders"],"prefix":"10.1016","volume":"29","author":[{"given":"Lorne A.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.08.010_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal storage disorders","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beem.2014.08.010_bib2","first-page":"13","article-title":"Gaucher disease and other storage disorders","volume":"2012","author":"Grabowski","year":"2012"},{"key":"10.1016\/j.beem.2014.08.010_bib3","first-page":"855","article-title":"High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews","volume":"49","author":"Zimran","year":"1991"},{"key":"10.1016\/j.beem.2014.08.010_bib4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.08.010_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.beem.2014.08.010_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-6-16","article-title":"Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders","volume":"6","author":"Hollak","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.08.010_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MOP.0b013e32831ec338","article-title":"Measurement of bone density in the pediatric population","volume":"21","author":"Bogunovic","year":"2009","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.beem.2014.08.010_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10545-012-9476-z","article-title":"Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients","volume":"35","author":"Ciana","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib12","first-page":"1380","article-title":"Osteomyelitis in Gaucher disease","volume":"68","author":"Bell","year":"1986"},{"key":"10.1016\/j.beem.2014.08.010_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00003086-199905000-00029","article-title":"Risk factors for osteonecrosis in patients with type 1 Gaucher's disease","volume":"362","author":"Rodrigue","year":"1999","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.beem.2014.08.010_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"de Fost","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beem.2014.08.010_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.21384","article-title":"Gaucher disease: resetting the clinical and scientific agenda","volume":"84","author":"Mistry","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beem.2014.08.010_bib16","first-page":"134","article-title":"Weather conditions can influence rheumatic diseases","volume":"47","author":"Verg\u00e9s","year":"2004"},{"key":"10.1016\/j.beem.2014.08.010_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","article-title":"An overview on bone manifestations in Gaucher disease","volume":"160","author":"Mikosch","year":"2010","journal-title":"Wien Med Wochenschr"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2014.08.010_bib18","first-page":"A13","article-title":"Imaging and 0quantifying skeletal involvement in Gaucher disease","volume":"75","author":"Maas","year":"2002"},{"key":"10.1016\/j.beem.2014.08.010_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","article-title":"Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease","volume":"27","author":"Hollak","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","article-title":"Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy","volume":"28","author":"Ciana","year":"2005","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.08.010_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beem.2014.08.010_bib23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.beem.2014.08.010_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A\u00a0phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beem.2014.08.010_bib25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beem.2014.08.010_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/epr.09.54","article-title":"Gaucher disease: a model disorder for biomarker discovery","volume":"6","author":"Boot","year":"2009","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.beem.2014.08.010_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.berh.2011.10.015","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone","volume":"25","author":"Mikosch","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.beem.2014.08.010_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","article-title":"Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease","volume":"28","author":"Drugan","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","article-title":"Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy","volume":"28","author":"Schiffmann","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.beem.2014.08.010_bib31","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.08.010_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.gene.2013.09.072","article-title":"Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease","volume":"532","author":"Mucci","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.beem.2014.08.010_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0140-6736(84)92579-0","article-title":"Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate","volume":"2","author":"Harinck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.08.010_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/08820139.2013.822766","article-title":"The role of cytokines in inflammatory bone loss","volume":"42","author":"Souza","year":"2013","journal-title":"Immunol Invest"},{"key":"10.1016\/j.beem.2014.08.010_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10","volume":"90","author":"Allen","year":"1997","journal-title":"QJM"},{"key":"10.1016\/j.beem.2014.08.010_bib36","series-title":"Cytokines in Gaucher's disease","author":"Barak","year":"1999"},{"key":"10.1016\/j.beem.2014.08.010_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","article-title":"Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease","volume":"23","author":"Hollak","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0925-4439(96)00056-7","article-title":"Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease","volume":"1317","author":"Michelakakis","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2014.08.010_bib39","first-page":"1969","article-title":"Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K","volume":"96","author":"Moran","year":"2000"},{"key":"10.1016\/j.beem.2014.08.010_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2164-12-20","article-title":"Global gene expression profile progression in Gaucher disease mouse models","volume":"12","author":"Xu","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.beem.2014.08.010_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2164-12-20","article-title":"Global gene expression profile progression in Gaucher disease mouse models","volume":"12","author":"Sun","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.beem.2014.08.010_bib42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"van Breemen","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2014.08.010_bib43","first-page":"284836","article-title":"Interleukin-10 inhibits bone resorption: a potential therapeutic Strategy In Periodontitis and other bone loss diseases","volume":"2014","author":"Zhang","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.beem.2014.08.010_bib44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1442-200X.2007.02502.x","article-title":"Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease","volume":"49","author":"Yoshino","year":"2007","journal-title":"Pediatr Int"},{"key":"10.1016\/j.beem.2014.08.010_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beem.2014.08.010_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0009-8981(77)90265-0","article-title":"Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate","volume":"80","author":"Chambers","year":"1977","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.beem.2014.08.010_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/08916930701694667","article-title":"Tartrate-resistant acid phosphatase (TRAP) and the osteoclast\/immune cell dichotomy","volume":"41","author":"Hayman","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.beem.2014.08.010_bib48","first-page":"666","article-title":"Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation","volume":"123","author":"Lotinun","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2014.08.010_bib49","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","article-title":"Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome","volume":"114","author":"Campeau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beem.2014.08.010_bib50","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.08.010_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"ERM"},{"key":"10.1016\/j.beem.2014.08.010_bib52","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1073\/pnas.96.11.6296","article-title":"Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX","volume":"96","author":"Triggs-Raine","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.08.010_bib53","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-011-9343-3","article-title":"A\u00a0complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis","volume":"34","author":"Imundo","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.010_bib54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","article-title":"Growth charts for patients affected with Morquio A disease","volume":"146A","author":"Monta\u00f1o","year":"2008","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.beem.2014.08.010_bib55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00256-013-1797-y","article-title":"Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose","volume":"43","author":"Lachman","year":"2014","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.beem.2014.08.010_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1546-0096-7-18","article-title":"Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis","volume":"7","author":"Cimaz","year":"2009","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.beem.2014.08.010_bib57","doi-asserted-by":"crossref","first-page":"v13","DOI":"10.1093\/rheumatology\/ker395","article-title":"Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator","volume":"50","author":"Clarke","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.beem.2014.08.010_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/labinvest.3780345","article-title":"Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses","volume":"81","author":"Simonaro","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/j.beem.2014.08.010_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","article-title":"Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models","volume":"57","author":"Simonaro","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.beem.2014.08.010_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","article-title":"Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases","volume":"172","author":"Simonaro","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beem.2014.08.010_bib61","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.08.010_bib62","first-page":"85","article-title":"Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation","volume":"3","author":"Simonaro","year":"2010"},{"key":"10.1016\/j.beem.2014.08.010_bib63","doi-asserted-by":"crossref","first-page":"e54459","DOI":"10.1371\/journal.pone.0054459","article-title":"Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses","volume":"8","author":"Schuchman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2014.08.010_bib64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ymgme.2009.03.005","article-title":"Mechanism of shortened bones in mucopolysaccharidosis VII","volume":"97","author":"Metcalf","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.010_bib65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymgme.2008.07.003","article-title":"Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy","volume":"95","author":"Herati","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.010_bib66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/iep.12033","article-title":"Characterization of joint disease in mucopolysaccharidosis type I mice","volume":"94","author":"de Oliveira","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.beem.2014.08.010_bib67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jor.21030","article-title":"Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII","volume":"28","author":"Smith","year":"2010","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.beem.2014.08.010_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymgme.2012.03.014","article-title":"Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII","volume":"107","author":"Smith","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.010_bib69","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2353\/ajpath.2009.090211","article-title":"Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities","volume":"175","author":"Wilson","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beem.2014.08.010_bib70","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2014.08.010_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age\u2013a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin Genet"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:49:46Z","timestamp":1761497386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1521690X14001018"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.08.010","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}